These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 7295103

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Design analyses of a new selective filtration system for removal of uremic toxins.
    Smeby LC, Jørstad S, Wilderøe TE.
    Clin Nephrol; 1980 Mar; 13(3):125-32. PubMed ID: 7379362
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L, Petrović J, Potić J.
    Acta Med Iugosl; 1990 Mar; 44(2):117-28. PubMed ID: 2162129
    [Abstract] [Full Text] [Related]

  • 27. Short-term evaluation of charcoal hemoperfusion combined with dialysis in uremic patients.
    Winchester JF, Apiliga MT, Kennedy AC.
    Kidney Int Suppl; 1976 Dec; (7):S315-9. PubMed ID: 1070554
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Biochemical and clinical evidence for uremic toxicity.
    Bouré T, Vanholder R.
    Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622
    [Abstract] [Full Text] [Related]

  • 31. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K, Kidawa Z, Walasek L, Lutz W.
    Pol Tyg Lek; 1978 Feb 13; 33(7):257-9. PubMed ID: 758030
    [No Abstract] [Full Text] [Related]

  • 32. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G, Diana L, Di Giovannandrea R, Sagliaschi G.
    ASAIO J; 1996 Feb 13; 42(1):64-7. PubMed ID: 8808461
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evidence that urea is a better surrogate marker of uremic toxicity than creatinine.
    Mehrotra R, Saran R, Nolph KD, Moore HL, Khanna R.
    ASAIO J; 1997 Feb 13; 43(5):M858-61. PubMed ID: 9360168
    [Abstract] [Full Text] [Related]

  • 37. Results of improvement in adequacy of intermittent hemodialysis in uremic patients.
    Grzegorzewska AE, Banachowicz W, Leander M.
    Rocz Akad Med Bialymst; 2005 Feb 13; 50():314-8. PubMed ID: 16358991
    [Abstract] [Full Text] [Related]

  • 38. Initial clinical evaluation of plasma dialysis.
    Snyder D, Pulido LB.
    Trans Am Soc Artif Intern Organs; 1970 Feb 13; 16():103-6. PubMed ID: 5460440
    [No Abstract] [Full Text] [Related]

  • 39. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
    Janda K, Stompór T, Gryz E, Szczudlik A, Drozdz M, Kraśniak A, Sułowicz W.
    Przegl Lek; 2007 Feb 13; 64(6):423-30. PubMed ID: 18159852
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.